These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18839776)

  • 61. [Inhibitors of hepatitis C virus--current standards and status of investigations].
    Godzik P; Komorowski M; Cielecka-Kuszyk J; Madaliński K
    Przegl Epidemiol; 2010; 64(4):473-8. PubMed ID: 21473060
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New targets for antiviral therapy of chronic hepatitis C.
    Bühler S; Bartenschlager R
    Liver Int; 2012 Feb; 32 Suppl 1():9-16. PubMed ID: 22212566
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Current and future treatment of hepatitis C.
    Manns MP; Cornberg M; Wedemeyer H
    Indian J Gastroenterol; 2001 Mar; 20 Suppl 1():C47-51. PubMed ID: 11293180
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Infectious disease. Despite setbacks, optimism on drugs for hepatitis C.
    Cohen J
    Science; 2012 Sep; 337(6101):1450-1. PubMed ID: 22997303
    [No Abstract]   [Full Text] [Related]  

  • 65. Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
    Li S; Kodama EN; Inoue Y; Tani H; Matsuura Y; Zhang J; Tanaka T; Hattori T
    Antivir Chem Chemother; 2010 Aug; 20(6):239-48. PubMed ID: 20710064
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hepatitis C virus therapies: current treatments, targets and future perspectives.
    Walker MP; Appleby TC; Zhong W; Lau JY; Hong Z
    Antivir Chem Chemother; 2003 Jan; 14(1):1-21. PubMed ID: 12790512
    [TBL] [Abstract][Full Text] [Related]  

  • 67. R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus.
    Toniutto P; Fabris C; Bitetto D; Fumolo E; Fornasiere E; Pirisi M
    IDrugs; 2008 Oct; 11(10):738-49. PubMed ID: 18828074
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New treatments for chronic hepatitis C: an overview for paediatricians.
    Serranti D; Indolfi G; Resti M
    World J Gastroenterol; 2014 Nov; 20(43):15965-74. PubMed ID: 25473150
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy.
    Martin B; Hennecke N; Lohmann V; Kayser A; Neumann-Haefelin C; Kukolj G; Böcher WO; Thimme R
    J Hepatol; 2014 Sep; 61(3):538-43. PubMed ID: 24905492
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities.
    Shimakami T; Lanford RE; Lemon SM
    Curr Opin Pharmacol; 2009 Oct; 9(5):537-44. PubMed ID: 19762279
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Advances in therapy for chronic hepatitis C.
    Fried MW
    Clin Liver Dis; 2001 Nov; 5(4):1009-23. PubMed ID: 11685792
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Therapy of acute hepatitis C: a review of literature.
    Santantonio T; Fasano M
    Curr Pharm Des; 2008; 14(17):1686-9. PubMed ID: 18673192
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.
    Durantel D
    Curr Opin Investig Drugs; 2009 Aug; 10(8):860-70. PubMed ID: 19649930
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The role of HCV proteins on treatment outcomes.
    Kumthip K; Maneekarn N
    Virol J; 2015 Dec; 12():217. PubMed ID: 26666318
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hepatitis C virus infection and immunomodulatory therapies.
    Forde KA; Reddy KR
    Clin Liver Dis; 2009 Aug; 13(3):391-401. PubMed ID: 19628156
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta.
    Shiratori Y; Perelson AS; Weinberger L; Imazeki F; Yokosuka O; Nakata R; Ihori M; Hirota K; Ono N; Kuroda H; Motojima T; Nishigaki M; Omata M
    J Hepatol; 2000 Aug; 33(2):313-22. PubMed ID: 10952250
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anti-HCV drugs in the pipeline.
    Yang PL; Gao M; Lin K; Liu Q; Villareal VA
    Curr Opin Virol; 2011 Dec; 1(6):607-16. PubMed ID: 22440918
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.
    Furman PA; Lam AM; Murakami E
    Future Med Chem; 2009 Nov; 1(8):1429-52. PubMed ID: 21426058
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combination treatment with interferon and ribavirin for chronic hepatitis C.
    Davis GL
    Clin Liver Dis; 1999 Nov; 3(4):811-26. PubMed ID: 11291252
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.
    Tong J; Wang YW; Lu YA
    J Zhejiang Univ Sci B; 2012 Jan; 13(1):56-82. PubMed ID: 22205621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.